Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early CNI Avoidance

NCT01266148 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT01266148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01266148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early CNI Avoidance
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2009
Completion date
December 31, 2012
Enrollment
115 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

renal function and chronic allograft vasculopathy